[1] |
GRACIA-SANCHO J, MARRONE G, FERNÁNDEZ-IGLESIAS A. Hepatic microcirculation and mechanisms of portal hypertension[J]. Nat Rev Gastroenterol Hepatol, 2019, 16( 4): 221- 234. DOI: 10.1038/s41575-018-0097-3.
|
[2] |
European Association for the Study of the Liver. EASL Clinical Practice Guidelines for the management of patients with decompensated cirrhosis[J]. J Hepatol, 2018, 69( 2): 406- 460. DOI: 10.1016/j.jhep.2018.03.024.
|
[3] |
XU XY, DING HG, LI WG, et al. Chinese guidelines on the management of liver cirrhosis(abbreviated version)[J]. World J Gastroenterol, 2020, 26( 45): 7088- 7103. DOI: 10.3748/wjg.v26.i45.7088.
|
[4] |
EL-SHERIF O, JIANG ZG, TAPPER EB, et al. Baseline factors associated with improvements in decompensated cirrhosis after direct-acting antiviral therapy for hepatitis C virus infection[J]. Gastroenterology, 2018, 154( 8): 2111- 2121.e 8. DOI: 10.1053/j.gastro.2018.03.022.
|
[5] |
TSOCHATZIS EA, BOSCH J, BURROUGHS AK. Liver cirrhosis[J]. Lancet, 2014, 383( 9930): 1749- 1761. DOI: 10.1016/S0140-6736(14)60121-5.
|
[6] |
DE FRANCHIS R, BOSCH J, GARCIA-TSAO G, et al. Baveno Ⅶ-Renewing consensus in portal hypertension[J]. J Hepatol, 2022, 76( 4): 959- 974. DOI: 10.1016/j.jhep.2021.12.022.
|
[7] |
SHARMA S, ROY A. Recompensation in cirrhosis: current evidence and future directions[J]. J Clin Exp Hepatol, 2023, 13( 2): 329- 334. DOI: 10.1016/j.jceh.2022.08.002.
|
[8] |
ARAVINTHAN AD, BARBAS AS, DOYLE AC, et al. Characteristics of liver transplant candidates delisted following recompensation and predictors of such delisting in alcohol-related liver disease: a case-control study[J]. Transpl Int, 2017, 30( 11): 1140- 1149. DOI: 10.1111/tri.13008.
|
[9] |
MACKEN L, GELSON W, PRIEST M, et al. Efficacy of direct-acting antivirals: UK real-world data from a well-characterised predominantly cirrhotic HCV cohort[J]. J Med Virol, 2019, 91( 11): 1979- 1988. DOI: 10.1002/jmv.25552.
|
[10] |
SHEIKH NT, SHAUKAT MT, HUSSAIN A, et al. SVR achievement in triple therapy treated hepatitis C induced cirrhosis: A dual center retrospective cohort study[J]. Ann Med Surg(Lond), 2022, 80: 104193. DOI: 10.1016/j.amsu.2022.104193.
|
[11] |
POSE E, TORRENTS A, REVERTER E, et al. A notable proportion of liver transplant candidates with alcohol-related cirrhosis can be delisted because of clinical improvement[J]. J Hepatol, 2021, 75( 2): 275- 283. DOI: 10.1016/j.jhep.2021.02.033.
|
[12] |
GENTILE I, SCOTTO R, COPPOLA C, et al. Treatment with direct-acting antivirals improves the clinical outcome in patients with HCV-related decompensated cirrhosis: results from an Italian real-life cohort(Liver Network Activity-LINA cohort)[J]. Hepatol Int, 2019, 13( 1): 66- 74. DOI: 10.1007/s12072-018-9914-6.
|
[13] |
JANG JW, CHOI JY, KIM YS, et al. Long-term effect of antiviral therapy on disease course after decompensation in patients with hepatitis B virus-related cirrhosis[J]. Hepatology, 2015, 61( 6): 1809- 1820. DOI: 10.1002/hep.27723.
|
[14] |
RAO HY, WU N. Effect of nucleoside(acid) analogues on liver fibrosis in chronic hepatitis B[J]. Beijing Med, 2014, 36( 6): 421- 423. DOI: 10.15932/j.0253-9713.2014.06.013.饶慧瑛, 武楠. 核苷(酸)类似物长期治疗对慢性乙型肝炎肝纤维化的影响[J]. 北京医学, 2014, 36( 6): 421- 423. DOI: 10.15932/j.0253-9713.2014.06.013.
|
[15] |
NIKOLAIDIS N, VASSILIADIS T, GIOULEME O, et al. Effect of lamivudine treatment in patients with decompensated cirrhosis due to anti-HBe positive/HBeAg-negative chronic hepatitis B[J]. Clin Transplant, 2005, 19( 3): 321- 326. DOI: 10.1111/j.1399-0012.2005.00340.x.
|
[16] |
SHIM JH, LEE HC, KIM KM, et al. Efficacy of entecavir in treatment-naïve patients with hepatitis B virus-related decompensated cirrhosis[J]. J Hepatol, 2010, 52( 2): 176- 182. DOI: 10.1016/j.jhep.2009.11.007.
|
[17] |
XU X, WANG H, ZHAO W, et al. Recompensation factors for patients with decompensated cirrhosis: a multicentre retrospective case-control study[J]. BMJ Open, 2021, 11( 6): e043083. DOI: 10.1136/bmjopen-2020-043083.
|
[18] |
VILLANUEVA C, ALBILLOS A, GENESCÀ J, et al. Development of hyperdynamic circulation and response to β-blockers in compensated cirrhosis with portal hypertension[J]. Hepatology, 2016, 63( 1): 197- 206. DOI: 10.1002/hep.28264.
|
[19] |
COSTA D, SIMBRUNNER B, JACHS M, et al. Systemic inflammation increases across distinct stages of advanced chronic liver disease and correlates with decompensation and mortality[J]. J Hepatol, 2021, 74( 4): 819- 828. DOI: 10.1016/j.jhep.2020.10.004.
|
[20] |
VILLANUEVA C, ALBILLOS A, GENESCÀ J, et al. Bacterial infections adversely influence the risk of decompensation and survival in compensated cirrhosis[J]. J Hepatol, 2021, 75( 3): 589- 599. DOI: 10.1016/j.jhep.2021.04.022.
|
[21] |
BEDOSSA P. Reversibility of hepatitis B virus cirrhosis after therapy: who and why[J]. Liver Int, 2015, 35 Suppl 1: 78- 81. DOI: 10.1111/liv.12710.
|
[22] |
MØLLER S, BENDTSEN F. The pathophysiology of arterial vasodilatation and hyperdynamic circulation in cirrhosis[J]. Liver Int, 2018, 38( 4): 570- 580. DOI: 10.1111/liv.13589.
|
[23] |
TREBICKA J, AMOROS A, PITARCH C, et al. Addressing profiles of systemic inflammation across the different clinical phenotypes of acutely decompensated cirrhosis[J]. Front Immunol, 2019, 10: 476. DOI: 10.3389/fimmu.2019.00476.
|
[24] |
WANG Q, ZHAO H, DENG Y, et al. Validation of Baveno VII criteria for recompensation in entecavir-treated patients with hepatitis B-related decompensated cirrhosis[J]. J Hepatol, 2022, 77( 6): 1564- 1572. DOI: 10.1016/j.jhep.2022.07.037.
|
[25] |
NABATCHIKOVA EA, ABDURAKHMANOV DT, ROZINA TP, et al. Delisting and clinical outcomes of liver transplant candidates after hepatitis C virus eradication: A long-term single-center experience[J]. Clin Res Hepatol Gastroenterol, 2021, 45( 6): 101714. DOI: 10.1016/j.clinre.2021.101714.
|
[26] |
IWAKIRI Y, TREBICKA J. Portal hypertension in cirrhosis: Pathophysiological mechanisms and therapy[J]. JHEP Rep, 2021, 3( 4): 100316. DOI: 10.1016/j.jhepr.2021.100316.
|
[27] |
SAAB S. Portal hypertension[J]. Clin Liver Dis, 2019, 23( 4):-. DOI: 10.1016/j.cld.2019.08.001.
|
[28] |
VILLANUEVA C, ALBILLOS A, GENESCÀ J, et al. β blockers to prevent decompensation of cirrhosis in patients with clinically significant portal hypertension(PREDESCI): a randomised, double-blind, placebo-controlled, multicentre trial[J]. Lancet, 2019, 393( 10181): 1597- 1608. DOI: 10.1016/S0140-6736(18)31875-0.
|
[29] |
MONTEIRO S, GRANDT J, USCHNER FE, et al. Differential inflammasome activation predisposes to acute-on-chronic liver failure in human and experimental cirrhosis with and without previous decompensation[J]. Gut, 2021, 70( 2): 379- 387. DOI: 10.1136/gutjnl-2019-320170.
|
[30] |
YANG L, KWON J, POPOV Y, et al. Vascular endothelial growth factor promotes fibrosis resolution and repair in mice[J]. Gastroenterology, 2014, 146( 5): 1339- 1350.e 1. DOI: 10.1053/j.gastro.2014.01.061.
|
[31] |
SALEHI S, TAVABIE OD, VERMA S, et al. Serum microrna signatures in recovery from acute and chronic liver injury and selection for liver transplantation[J]. Liver Transpl, 2020, 26( 6): 811- 822. DOI: 10.1002/lt.25781.
|
[32] |
REIBERGER T, HOFER BS. The Baveno VII concept of cirrhosis recompensation[J]. Dig Liver Dis, 2023, 55( 4): 431- 441. DOI: 10.1016/j.dld.2022.12.014.
|
[33] |
MÉNDEZ-SÁNCHEZ N, PAL SC. New terms for fatty liver disease other than MAFLD: Time for a reality check[J]. J Hepatol, 2022, 77( 6): 1716- 1717. DOI: 10.1016/j.jhep.2022.08.009.
|
[34] |
ASRANI SK, DEVARBHAVI H, EATON J, et al. Burden of liver diseases in the world[J]. J Hepatol, 2019, 70( 1): 151- 171. DOI: 10.1016/j.jhep.2018.09.014.
|